These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34405209)

  • 1. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
    Kibble A
    Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competencies for Professionals in Health Economics and Outcomes Research: The ISPOR Health Economics and Outcomes Research Competencies Framework.
    Pizzi LT; Onukwugha E; Corey R; Albarmawi H; Murray J
    Value Health; 2020 Sep; 23(9):1120-1127. PubMed ID: 32940228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (November 4-6, 2019 - Copenhagen, Denmark).
    Kibble A
    Drugs Today (Barc); 2019 Nov; 55(11):713-718. PubMed ID: 31840686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Economics and Outcomes Research Knowledge Needs Assessment for Latin America.
    Hughes VS; Ferreira De Azeredo-Da-Silva AL; Hincapie AL
    Value Health Reg Issues; 2019 Dec; 20():2-6. PubMed ID: 30634087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Annual International Meeting. May 19-22, 2002. Arlington, Virginia, USA. Abstracts.
    Value Health; 2002; 5(3):117-294. PubMed ID: 12010559
    [No Abstract]   [Full Text] [Related]  

  • 9. Abstracts of the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Fourteenth Annual International Meeting. May 16-20, 2009. Orlando, Florida, USA.
    Value Health; 2009 May; 12(3):A1-203. PubMed ID: 19392734
    [No Abstract]   [Full Text] [Related]  

  • 10. Abstracts of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 9th Annual International Meeting. May 16-19, 2004, Arlington, Virginia, USA.
    Value Health; 2004; 7(3):219-393. PubMed ID: 15279015
    [No Abstract]   [Full Text] [Related]  

  • 11. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Annual International Meeting. May 20-23, 2001. Arlington, Virginia, USA. Abstracts.
    Value Health; 2001; 4(2):47-209. PubMed ID: 11700642
    [No Abstract]   [Full Text] [Related]  

  • 12. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference.
    Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):305-7. PubMed ID: 19670989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 9.
    Simpson A; Ramagopalan SV
    J Comp Eff Res; 2022 Nov; 11(16):1147-1149. PubMed ID: 35998008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics and outcomes research fellowship practices reviewed.
    Suh K; Gabriel S; Adams MA; Arcona S
    Res Social Adm Pharm; 2015; 11(2):280-7. PubMed ID: 25178521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 5th Annual European Congress. 3-5 November 2002. Rotterdam, The Netherlands. Abstracts.
    Value Health; 2002; 5(6):443-605. PubMed ID: 12371940
    [No Abstract]   [Full Text] [Related]  

  • 20. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Annual European Congress. 9-11 November 2003, Barcelona, Spain. Abstracts.
    Value Health; 2003; 6(6):605-829. PubMed ID: 14964251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.